PHOSPHINOTHRICIN


UNII	72P470U27C
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	IAJOBQBIJHVGMQ-BYPYZUCNSA-N
Smiles	CP(=O)(O)CC[C@H](N)C(=O)O
InChI	InChI=1S/C5H12NO4P/c1-11(9,10)3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)(H,9,10)/t4-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C5H12NO4P
Molecular Weight	181.13
AlogP	-4.02
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	4.0
Polar Surface Area	110.43
Molecular species	ZWITTERION
Aromatic Rings	0.0
Heavy Atoms	11.0

Assay Description	Organism	Bioactivity
Inhibition of Oryza sativa cv. Gigante vercellese (rice) glutamine synthetase assessed as inhibition of glutamine synthesis from glutamic acid at 1 mM after 15 min by biosynthetic assay	Oryza sativa	2.0 %
Inhibition of Oryza sativa cv. Gigante vercellese (rice) glutamine synthetase at 1 mM after 30 min by hemibiosynthetic assay	Oryza sativa	9.9 %
Inhibition of Oryza sativa cv. Gigante vercellese (rice) glutamine synthetase at 1 mM by transferase assay	Oryza sativa	25.7 %
Reversible inhibition of Oryza sativa cv. Gigante vercellese (rice) glutamine synthetase assessed as inhibition of glutamine synthesis from glutamic acid at 10 uM after 50 min by biosynthetic assay	Oryza sativa	None
Effect on amino acid pool in Oryza sativa cv. Gigante vercellese (rice) cells assessed as total amino acid content per gram fresh weight of culture at 0.5 mM after 48 hr (Rvb = 24.65 +/- 0.97 umol)	Oryza sativa	27.34 %
Effect on amino acid pool in Oryza sativa cv. Gigante vercellese (rice) cells assessed as glutamine content per gram fresh weight of culture at 0.5 mM after 48 hr (Rvb = 4.24 +/- 0.35 umol)	Oryza sativa	2.05 %
Effect on amino acid pool in Oryza sativa cv. Gigante vercellese (rice) cells assessed as serine content per gram freshweight of culture at 0.5 mM after 48 hr (Rvb = 0.60 +/- 0.09 umol)	Oryza sativa	1.38 %
Effect on amino acid pool in Oryza sativa cv. Gigante vercellese (rice) cells assessed as asparagine content per gram freshweight of culture at 0.5 mM after 48 hr (Rvb = 3.18 +/- 0.25 umol)	Oryza sativa	0.25 %
Effect on amino acid pool in Oryza sativa cv. Gigante vercellese (rice) cells assessed as glutamic acid content per gram freshweight of culture at 0.5 mM after 48 hr (Rvb = 0.75 +/- 0.07 umol)	Oryza sativa	3.86 %
Effect on amino acid pool in Oryza sativa cv. Gigante vercellese (rice) cells assessed as aspartic acid content per gram freshweight of culture at 0.5 mM after 48 hr (Rvb = 1.10 +/- 0.26 umol)	Oryza sativa	1.8 %
Inhibition of Oryza sativa cv. Gigante vercellese (rice) glutamine synthetase assessed as inhibition of glutamine synthesis from glutamic acid after 15 min by biosynthetic assay	Oryza sativa	44000.0 nM
Inhibition of Oryza sativa cv. Gigante vercellese (rice) glutamine synthetase after 30 min by hemibiosynthetic assay	Oryza sativa	49000.0 nM
Inhibition of Oryza sativa cv. Gigante vercellese (rice) glutamine synthetase by transferase assay	Oryza sativa	172000.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL145114
FDA SRS	72P470U27C
PDB	PPQ
PubChem	91619
SureChEMBL	SCHEMBL21986
ZINC	ZINC00902211

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).